Bioventus
BVS
103 hedge funds and large institutions have $222M invested in Bioventus in 2024 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 30 increasing their positions, 20 reducing their positions, and 19 closing their positions.
111% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 19
50% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 20
25% more capital invested
Capital invested by funds: $178M → $222M (+$44.3M)
23% more funds holding
Funds holding: 84 → 103 (+19)
6.56% more ownership
Funds ownership: 54% → 60.57% (+6.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
31% less call options, than puts
Call options by funds: $877K | Put options by funds: $1.28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.1M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.47M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.43M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.37M |
| 5 |
Renaissance Technologies
New York
|
+$2.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.57M |
| 2 |
Jane Street
New York
|
-$2.05M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$1.23M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$989K |
| 5 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
-$792K |
BVS Hedge Fund Activity: Q2 2024 in Review
103 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q2 2024, worth a combined $222M — up 25% from $178M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new BVS positions and 19 closed out — a net gain of 21 holders — while 30 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $10.1M. The largest seller was Nantahala Capital Management, cutting an estimated $2.57M.
- 103 institutional investors held Bioventus (BVS) as of Q2 2024, up from 84 in Q1 2024.
- Funds reported $222M of Bioventus stock for Q2 2024, up 25% quarter-over-quarter.
- 40 funds opened new Bioventus positions in Q2 2024 and 19 closed out, a net change of +21 holders.
- The largest Bioventus buyer in Q2 2024 was BlackRock, an estimated $10.1M added.
- The largest Bioventus seller in Q2 2024 was Nantahala Capital Management, an estimated $2.57M sold.
Based on aggregated 13F filings for Q2 2024.